OBJECTIVE: To characterize the dose-responsiveness of morphologic and biochemical chondral changes relative to mobility in mono-iodoacetate (MIA)-induced osteoarthritis (OA) in rats. METHODS: Rat mobility was assessed by biotelemetry. Articular lesions were characterized by macroscopic and histologic examinations. Cartilage proteoglycan metabolism was evaluated by the 1,9-dimethylmethylene blue dye binding assay and by radiosulfate incorporation in patellar cartilage. RESULTS: Spontaneous locomotor activity was rapidly, transiently, and dose-dependently decreased after MIA injection into rat knees (primary response). Thereafter, only high doses (0.3 mg and 3.0 mg) led to a secondary progressive long-term loss of spontaneous mobility on day 15, when subchondral bone was exposed. These 2 doses resulted in significant changes in cartilage proteoglycan concentration at day 15 and a strong inhibition of anabolism in the peripheral patellae by day 2, contrasting with the effects of lower doses (0.01, 0.03, and 0.1 mg). CONCLUSION: When a sufficient dose of MIA is used, this model can easily and quickly reproduce OA-like lesions and functional impairment in rats, similar to that observed in human disease. These parameters, as well as proteoglycan metabolism, could serve as indicators for studying chondroprotective drugs, or for evaluating the ability of imaging techniques to detect and evaluate chondral lesions.
OBJECTIVE: To characterize the dose-responsiveness of morphologic and biochemical chondral changes relative to mobility in mono-iodoacetate (MIA)-induced osteoarthritis (OA) in rats. METHODS:Rat mobility was assessed by biotelemetry. Articular lesions were characterized by macroscopic and histologic examinations. Cartilage proteoglycan metabolism was evaluated by the 1,9-dimethylmethylene blue dye binding assay and by radiosulfate incorporation in patellar cartilage. RESULTS: Spontaneous locomotor activity was rapidly, transiently, and dose-dependently decreased after MIA injection into rat knees (primary response). Thereafter, only high doses (0.3 mg and 3.0 mg) led to a secondary progressive long-term loss of spontaneous mobility on day 15, when subchondral bone was exposed. These 2 doses resulted in significant changes in cartilage proteoglycan concentration at day 15 and a strong inhibition of anabolism in the peripheral patellae by day 2, contrasting with the effects of lower doses (0.01, 0.03, and 0.1 mg). CONCLUSION: When a sufficient dose of MIA is used, this model can easily and quickly reproduce OA-like lesions and functional impairment in rats, similar to that observed in human disease. These parameters, as well as proteoglycan metabolism, could serve as indicators for studying chondroprotective drugs, or for evaluating the ability of imaging techniques to detect and evaluate chondral lesions.
Authors: B B Yao; G C Hsieh; J M Frost; Y Fan; T R Garrison; A V Daza; G K Grayson; C Z Zhu; M Pai; P Chandran; A K Salyers; E J Wensink; P Honore; J P Sullivan; M J Dart; M D Meyer Journal: Br J Pharmacol Date: 2007-11-12 Impact factor: 8.739
Authors: B A Christiansen; F Guilak; K A Lockwood; S A Olson; A A Pitsillides; L J Sandell; M J Silva; M C H van der Meulen; D R Haudenschild Journal: Osteoarthritis Cartilage Date: 2015-05-21 Impact factor: 6.576
Authors: Robby D Bowles; Brian A Mata; Richard D Bell; Timothy K Mwangi; Janet L Huebner; Virginia B Kraus; Lori A Setton Journal: Arthritis Rheumatol Date: 2014-03 Impact factor: 10.995
Authors: Tomoyuki Matsumoto; Gregory M Cooper; Burhan Gharaibeh; Laura B Meszaros; Guangheng Li; Arvydas Usas; Freddie H Fu; Johnny Huard Journal: Arthritis Rheum Date: 2009-05